Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

ADCT

Adc Therapeutics SA

Jun 18 • 04:00PM ET

2.72

Dollar change -0.10
Percentage change -3.55	%

Healthcare • Biotechnology • Switzerland • NYSE

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.76	Insider Own	20.15%	Shs Outstand	82.29M	Perf Week	-13.38%
Market Cap	261.75M	Forward P/E	-	EPS next Y	-1.58	Insider Trans	-0.32%	Shs Float	76.83M	Perf Month	-33.66%
Income	-226.56M	PEG	-	EPS next Q	-0.44	Inst Own	40.27%	Short Float	1.28%	Perf Quarter	-41.76%
Sales	68.62M	P/S	3.81	EPS this Y	35.76%	Inst Trans	4.65%	Short Ratio	1.64	Perf Half Y	71.07%
Book/sh	-2.35	P/B	-	EPS next Y	16.41%	ROA	-58.42%	Short Interest	0.98M	Perf Year	18.78%
Cash/sh	2.43	P/C	1.12	EPS next 5Y	15.80%	ROE	-705.53%	52W Range	0.36 - 6.04	Perf YTD	63.86%
Dividend Est.	-	P/FCF	-	EPS past 5Y	84.52%	ROI	-	52W High	-54.97%	Beta	1.57
Dividend TTM	-	Quick Ratio	4.35	Sales past 5Y	91.46%	Gross Margin	92.27%	52W Low	655.75%	ATR (14)	0.35
Dividend Ex-Date	-	Current Ratio	4.61	EPS Y/Y TTM	-9.52%	Oper. Margin	-217.40%	RSI (14)	30.04	Volatility	11.25% 10.28%
Employees	162	Debt/Eq	-	Sales Y/Y TTM	-62.38%	Profit Margin	-330.17%	Recom	1.43	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	23.23%	Payout	-	Rel Volume	0.68	Prev Close	2.82
Sales Surprise	0.05%	EPS Surprise	-0.76%	Sales Q/Q	-4.94%	Earnings	May 06 BMO	Avg Volume	600.55K	Price	2.72
SMA20	-21.24%	SMA50	-33.83%	SMA200	2.43%	Trades		Volume	407,440	Change	-3.55%

Date	Action	Analyst	Rating Change	Price Target Change
May-30-24	Initiated	Cantor Fitzgerald	Overweight
Mar-28-24	Initiated	Guggenheim	Buy	$11
Aug-10-23	Upgrade	JP Morgan	Underweight → Neutral
Apr-24-23	Downgrade	BofA Securities	Neutral → Underperform	$7 → $2
Dec-06-22	Initiated	CapitalOne	Overweight	$12
Nov-09-22	Downgrade	BofA Securities	Buy → Neutral	$14 → $7
Sep-21-22	Initiated	JP Morgan	Overweight	$5
Sep-09-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $11
Nov-09-21	Initiated	Wolfe Research	Outperform	$44
Aug-17-21	Resumed	Jefferies	Buy	$40
Aug-09-21	Initiated	RBC Capital Mkts	Outperform	$33
Jun-15-21	Initiated	Cantor Fitzgerald	Overweight	$13
Dec-03-20	Initiated	Stifel	Hold	$42
Oct-29-20	Initiated	H.C. Wainwright	Buy	$47
Jun-09-20	Initiated	Cowen	Outperform
Jun-09-20	Initiated	BofA/Merrill	Buy	$45

Show Previous Ratings

Jun-03-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +5.74%
May-30-24 07:15AM	ADC Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 07:15AM	ADC Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
May-09-24 07:01PM	Insider Sale: CEO Ameet Mallik Sells 29,731 Shares of ADC Therapeutics SA (ADCT) (GuruFocus.com) -5.91%
07:15AM	ADC Therapeutics to Participate in 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-07-24 08:55AM	ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript (Insider Monkey) +8.54%
08:44AM	HC Wainwright Adjusts Price Target on ADC Therapeutics to $8 From $9, Maintains Buy Rating (MT Newswires)
May-06-24 10:53AM	ADCT Stock Earnings: ADC Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) -9.18%
08:22AM	ADC Therapeutics Launches $105 Million Offering; Shares Up 2% Pre-Bell (MT Newswires)
07:30AM	ADC Therapeutics Announces $105 Million Underwritten Offering of Common Shares and Pre-Funded Warrants (GlobeNewswire)
07:20AM	ADC Therapeutics SA (ADCT) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:55AM	ADC Therapeutics SA's Cancer Drug Candidate Shows High Response Rate in Phase 2 Trial (MT Newswires)
06:10AM	ADC Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
06:00AM	ADC Therapeutics Announces Initial Data from Investigator-Initiated Phase 2 Clinical Trial of ZYNLONTA in Patients with Relapsed/Refractory Marginal Zone Lymphoma (GlobeNewswire)
May-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire) +6.80%
07:00AM	ADC Therapeutics to Host First Quarter 2024 Financial Results and Pipeline Update Conference Call on May 6, 2024 (GlobeNewswire)
Apr-16-24 08:30AM	ADC Therapeutics Accelerates R&D with Genedata Biologics (PR Newswire)
Apr-04-24 07:00AM	ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma (GlobeNewswire) +6.32%
Apr-03-24 07:00AM	ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024 (GlobeNewswire)
Apr-01-24 04:05PM	ADC Therapeutics Makes Grants to New Employees Under Inducement Plan (GlobeNewswire)
Mar-15-24 12:30PM	ADC Therapeutics SA (NYSE:ADCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 05:16AM	Q4 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 08:51AM	ADC Therapeutics SA (ADCT) Reports Mixed 2023 Financial Results Amid Strategic Reset (GuruFocus.com) -12.36%
08:20AM	ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-06-24 07:15AM	ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit (GlobeNewswire)
07:00AM	ADC Therapeutics to Host Fourth Quarter and Year-End 2023 Financial Results Conference Call on March 13, 2024 (GlobeNewswire)
Mar-05-24 05:45PM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-27-24 07:00AM	ADC Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-20-24 10:00AM	Earnings Preview: ADC Therapeutics SA (ADCT) Q4 Earnings Expected to Decline (Zacks) -8.88%
Feb-16-24 03:57AM	15 Top Performing European Stocks So Far in 2024 (Insider Monkey) +6.44%
Feb-15-24 11:57AM	The 3 Biotech Stocks That Could Make Your February Unforgettable (InvestorPlace)
Feb-08-24 01:15PM	The 3 Most Undervalued Biotech Stocks to Buy in February 2024 (InvestorPlace)
Jan-19-24 01:05PM	ADC Therapeutics (ADCT) Rises 43% in a Month: Here's Why (Zacks)
09:40AM	Is ADC Therapeutics (ADCT) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-04-24 10:05AM	ADC Therapeutics, Aldeyra start off New Year with program discontinuations (FierceBiotech.com) +13.25%
07:15AM	ADC Therapeutics Regains Compliance with NYSE Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Provides Business Updates (GlobeNewswire)
Dec-12-23 05:15AM	ADC Therapeutics Announces Initial Results from Investigator-Initiated Phase 2 Clinical Trial Evaluating ZYNLONTA in Combination with Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma (FL) (GlobeNewswire)
Nov-20-23 02:40AM	Sobi to present new data at ASH 2023 Annual Meeting (PR Newswire)
Nov-15-23 03:00AM	Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors (GlobeNewswire) +6.15%
Nov-08-23 01:26PM	ADC Therapeutics SA (NYSE:ADCT) Q3 2023 Earnings Call Transcript (Insider Monkey) -17.26%
01:03AM	Q3 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents)
Nov-07-23 08:15AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -15.97%
07:15AM	ADC Therapeutics Receives NYSE Notice of Non-Compliance With Continued Listing Standards (GlobeNewswire)
07:00AM	ADC Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-06-23 07:00AM	ADC Therapeutics to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +7.87%
Nov-02-23 05:50PM	Puma Biotech (PBYI) Tops Q3 Earnings Estimates (Zacks) +14.27%
10:10AM	ADC Therapeutics Announces Abstracts Accepted for Presentation at the 65th ASH Annual Meeting (GlobeNewswire)
Nov-01-23 10:01AM	Ligand Pharmaceuticals (LGND) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-31-23 10:01AM	ADC Therapeutics SA (ADCT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Oct-24-23 07:00AM	ADC Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on November 7, 2023 (GlobeNewswire)
Oct-04-23 04:00AM	Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO (GlobeNewswire)
Sep-05-23 07:00AM	ADC Therapeutics to Participate in September Investor Conferences (GlobeNewswire) -7.38%
Aug-30-23 07:33PM	ADC Therapeutics Announces Updates on ZYNLONTA® LOTIS Clinical Trial Programs at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) (GlobeNewswire)
Aug-14-23 10:51AM	Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37% (Zacks)
Aug-11-23 10:53AM	Catalyst (CPRX) Q2 Earnings & Sales Top, 2023 Outlook Raised (Zacks)
Aug-10-23 10:31AM	Novo Nordisk (NVO) Q2 Earnings and Sales Miss, 2023 View Up (Zacks) +7.33%
Aug-09-23 12:09PM	Horizon (HZNP) Q2 Earnings Top, Krystexxa & Uplizna Boost Sales (Zacks) -6.25%
Aug-08-23 11:01PM	Q2 2023 ADC Therapeutics SA Earnings Call (Thomson Reuters StreetEvents) +11.89%
10:48AM	Zoetis' (ZTS) Q2 Earnings and Revenues Surpass Estimates (Zacks)
08:15AM	ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	ADC Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-07-23 05:25PM	MannKind (MNKD) Reports Break-Even Earnings for Q2 (Zacks)
Aug-04-23 08:40AM	Intra-Cellular (ITCI) Q2 Earnings & Sales Top, '23 View Raised (Zacks)
08:12AM	Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat (Zacks)
Aug-03-23 11:48AM	Corcept (CORT) Beats on Q2 Earnings, Ups '23 Sales View (Zacks)
11:45AM	Editas' (EDIT) Q2 Earnings Beat, Sales Miss, Pipeline in Focus (Zacks)
08:02AM	Acadia (ACAD) Q2 Earnings & Revenues Beat Estimates, '23 View Up (Zacks)
Aug-02-23 12:45PM	Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated (Zacks)
12:42PM	Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates (Zacks)
Aug-01-23 10:45AM	Apellis (APLS) Q2 Earnings Top, Syfovre Sales Boost Revenues (Zacks)
07:22AM	Are Investors Undervaluing ADC Therapeutics SA (NYSE:ADCT) By 27%? (Simply Wall St.)
07:00AM	ADC Therapeutics to Host Second Quarter 2023 Financial Results Conference Call on August 8, 2023 (GlobeNewswire)
Jul-28-23 08:02AM	Dr. Reddy's (RDY) Q1 Earnings and Revenues Beat Estimates (Zacks)
Jul-26-23 08:52AM	Bayer (BAYRY) Cuts 2023 Outlook, Reports Preliminary Q2 Results (Zacks)
Jul-24-23 01:20PM	Alnylam (ALNY) to Co-Develop Hypertension Drug With Roche (Zacks) -7.75%
11:12AM	Horizon's (HZNP) Daxdilimab Fails to Meet Goal in Lupus Study (Zacks)
07:21AM	Overland ADCT BioPharma Announces NMPA Accepts Biologics License Application and Grants Priority Review for ZYNLONTA® for Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (GlobeNewswire)
Jul-21-23 01:22PM	GSK Gears Up for Q2 Earnings: Will It Surpass Estimates? (Zacks) -5.33%
07:44AM	Astria (ATXS) Rises 5% on Fast Track Tag for Angioedema Drug (Zacks)
Jul-20-23 04:05PM	ADC Therapeutics Announces Plan to Discontinue the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients (GlobeNewswire)
Jul-19-23 09:59AM	Adial (ADIL) Shares Up 43% in the Past Week: Here's Why (Zacks)
Jul-18-23 11:04AM	Ligand (LGND) Offers $15M in Cash to Acquire All Novan Assets (Zacks)
Jul-17-23 10:59AM	Theseus (THRX) Falls 72% on Decision to Discontinue GIST Study (Zacks)
10:06AM	Alnylam (ALNY) Posts Upbeat Data From Alzheimer's Disease Study (Zacks)
Jul-14-23 10:56AM	Halozyme (HALO) Rises 5% as Ocrevus SC Meets Goals in MS Study (Zacks)
09:55AM	ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
08:03AM	Acadia (ACAD) Expands Existing Licensing Deal With Neuren (Zacks)
Jul-13-23 09:35AM	After Plunging -34.06% in 4 Weeks, Here's Why the Trend Might Reverse for ADC Therapeutics SA (ADCT) (Zacks)
07:08AM	AVROBIO (AVRO) to Explore Strategic Options, Stock Rises 46% (Zacks)
Jul-12-23 10:27AM	ADC Therapeutics (ADCT) Dips on Halting Zynlonta Study (Zacks) -18.38%
Jul-11-23 12:50PM	Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study (Zacks) -21.94%
10:24AM	Novavax (NVAX) to Receive $350M From Canada, Stock Rises 30% (Zacks)
07:17AM	ADC Therapeutics pauses enrolment in mid-stage trial for cancer therapy (Reuters)
07:00AM	ADC Therapeutics Announces Voluntary Pause of Enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) and Rituximab in Unfit or Frail Previously Untreated DLBCL Patients (GlobeNewswire)
Jun-15-23 07:15AM	ADC Therapeutics Announces Evolution of Board of Directors (GlobeNewswire)
Jun-09-23 07:15AM	ADC Therapeutics Announces Updated LOTIS-2 Results Demonstrating Durable, Long-Term Responses of ZYNLONTA® in Relapsed/Refractory DLBCL (GlobeNewswire)
Jun-01-23 07:15AM	ADC Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-11-23 12:33PM	ADC Therapeutics Announces Updated Results from LOTIS-2 Trial to be Presented at the European Hematology Association 2023 Hybrid Congress (Business Wire)

ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Azelby Robert	Director	Jun 17 '24	Sale	2.89	6,995	20,216	53,005	Jun 18 09:45 PM
BIZZARI JEAN-PIERRE	Director	Jun 17 '24	Sale	2.89	6,995	20,216	79,502	Jun 18 09:43 PM
Sandor Victor	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,886	Jun 18 09:37 PM
Squarer Ron	Director	Jun 17 '24	Sale	2.89	6,995	20,216	80,663	Jun 18 09:35 PM
Monges Viviane	Director	Jun 17 '24	Sale	2.89	1,437	4,153	106,627	Jun 18 09:40 PM
Pfisterer Thomas	Director	Jun 17 '24	Sale	2.89	1,437	4,153	213,900	Jun 18 09:38 PM
Hug Peter	Director	Jun 17 '24	Sale	2.89	1,193	3,448	182,644	Jun 18 09:41 PM
MALLIK AMEET	Chief Executive Officer	May 07 '24	Sale	4.48	29,731	133,195	1,167,348	May 09 04:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ADCT

Adc Therapeutics SA

Upgrade your FINVIZ experience